Rémy Burcelin explains how understanding the link between gut microbiota, metabolic syndrome and cancer could be useful from a therapeutic point of view.

CosmosID detects and identifies microorganisms of all kinds using next-generation sequencing. We discussed CosmosID's approach with Arne Materna, the company's VP Product.

Radiotherapy against prostate cancer may cause serious intestinal side effects. We discussed the impact of the local microbiota with Miguel Reis Ferreira.

The existence of a tumor microbiota have a lot of implications. We discussed this topic with Sandrine Miller-Montgomery (UC San Diego).

The modulation of the microbiota impacts on the efficacy of the new anti-PD-1 cancer therapies. We discuss it with Giorgio Trinchieri (NIH, USA).